CGEN

1.8402.13%
AC

Anat Cohen-Dayag

Executive Chair

Dr. Anat Cohen-Dayag, Ph.D., served as an Independent Director at Gamida Cell Ltd since January 28, 2022 until March 2023. She served as Chief Executive Officer and President at Compugen Ltd since March 2010 until September 2025 and is its Executive Chair since September 2025. She served as Co-Chief Executive Officer at Compugen Ltd since June 2009 until March 2010. Under her leadership, Compugen transformed from a service provider in the field of computational biology to a therapeutic discovery and development company advancing an innovative immuno-oncology pipeline originating computational discovery platforms. She served as Vice President of Research & Development at Compugen Ltd. from November 2008. She served as Vice President of Diagnostic Biomarkers at Compugen Ltd. from January 1, 2006 to January 2007 and served as its Vice President of Diagnostic Biomarkers and Therapeutic/Drug Targets from January 2007 to November 2008. She joined Compugen in 2002 where she served as Director of Diagnostics since 2005. Prior to joining Compugen, she served as Head of Research and Development and member of the Executive Management at Mindsense Biosystems Ltd. Prior to Mindsense Biosystems, she served as a scientist at the R&D department of Orgenics Ltd. She has been Director of Compugen Ltd. since February 10, 2014. She serves as a Director of Ramot at Tel Aviv University Ltd. She serves as Director at The Technology Innovation Momentum Management Company (formerly known as Ramot at Tel Aviv University Ltd., Investment Arm). She is a member of the Bio-Convergence Initiative of the Israel Academy of Sciences and Humanities. She holds a B.Sc. in Biology from Ben-Gurion University, Israel and an M.Sc. in Chemical Immunology and a Ph.D. in Cellular Biology, both from the Weizmann Institute of Science, Israel. she is also a member of the Board of Directors of Pyxis Limited.

Positions